Trials / Terminated
TerminatedNCT04524962
Study of Descartes-30 in Acute Respiratory Distress Syndrome
Phase I/IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Cartesian Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Descartes 30 | Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases. |
Timeline
- Start date
- 2021-02-23
- Primary completion
- 2022-09-09
- Completion
- 2023-09-09
- First posted
- 2020-08-24
- Last updated
- 2024-10-29
- Results posted
- 2024-10-29
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04524962. Inclusion in this directory is not an endorsement.